Invicta Animal Health has been appointed exclusive UK distributor of EquiChek, a novel rapid screening test to assess the level of Serum Amyloid A – a major acute phase protein of inflammation in horses.
Invicta Animal Health has been appointed exclusive UK distributor of EquiChek, a novel rapid screening test, using whole blood, to assess the level of Serum Amyloid A (SAA), which is a major acute phase protein of inflammation in horses.
EquiChek is the first test that is able to provide a visual semi-quantitative result within 15 minutes.
The test (pictured) will display 4 lines for a normal level of SAA and sequentially fewer lines depending on the severity of the inflammation.
Invicta managing director Rob Watkins said: “Monitoring SAA levels in horses is a well documented method of indicating a variety of conditions and for assessing health/inflammatory status prior to performance. However, the needs for equipment and time to perform the tests have always limited the situations in which it can be used.
“EquiChek changes all that. A stableside test for SAA means that monitoring real-time becomes a reality. Whether for tailoring antibiotic therapy, to check pre-breeding health status through to pre-competition health assessment, the applications are literally endless“.
- For further information, telephone 01403 791313 or visit Invicta Animal Health’s website